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coadministered drugs. Probably by the same mechanism, efavirenz-based HIV therapy affects the
disposition of endogenous compounds, but this effect is difﬁcult to directly link with efavirenz because
it is used in combination with other drugs.
Objectives: To explore the effect of efavirenz monotherapy on biochemical laboratory values in a clinical
trial of healthy volunteers.
Methods: Men and women (aged 18–49 years) with body mass index r32 who were assessed to be
healthy based on medical history, physical examination, and standard laboratory screening received a
single (600 mg) and multiple doses (600 mg/d for 17 days) of efavirenz orally. This trial was designed to
determine the pharmacokinetics and drug interactions of efavirenz. As part of this study, analysis of
serum chemistries that were measured at study entry (screening) and 1 week after completion of the
multiple dose study (exit) is reported.
Results: Data from 60 subjects who fully completed and 13 subjects who partially completed the study
are presented. Total bilirubin was substantially reduced at exit (by 30%, with large intersubject
variability) compared with screening values (P o 0.0001). The percent changes were in part explained
by the intersubject differences in baseline total bilirubin because there was a signiﬁcant correlation
between baseline (screening) values and percent change at exit (r ¼ 0.50; P o 0.0001). Hemoglobin and
absolute neutropenia were also substantially decreased at exit compared with screening, but this may be
due to intensive blood sampling rather than direct effect of efavirenz on these parameters. No signiﬁcant
correlation was found between percent change in hemoglobin versus percent change in bilirubin,
indicating the effect of efavirenz on bilirubin is independent of its effects on hemoglobin.
Conclusions: Efavirenz monotherapy signiﬁcantly lowers plasma total bilirubin concentration in healthy
volunteers independent of its effect on hemoglobin, probably through its effects on bilirubin metabolism
and transport (uptake and efﬂux). These ﬁndings help explain reversal by efavirenz of hyperbilirubine-
mia induction observed by some protease inhibitor antiretroviral drugs (eg, atazanavir). Besides its well-
documented role on drug interactions, efavirenz may alter the disposition of endogenous compounds
relevant in physiologic homeostasis through its interaction with drug metabolizing enzymes and/or drug
transporters. ClinicalTrials.gov identiﬁer: NCT00668395.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Inc. This is an open access article u
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Highly active antiretroviral therapy (HAART), a combination of
at least 3 antiretroviral drugs, effectively suppresses viralnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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patients with HIV infection with AIDs. The introduction of HAART
in 1996 was a landmark treatment change that considerably
improved the prognosis of patients infected with HIV by reducing
AIDS-related morbidity and mortality.1 Because of HAART and
better management of opportunistic infections, HIV, which was
once fatal, is now considered a chronic manageable infection that
requires lifelong drug therapy. Because HIV has gradually changed
from an acute to chronic disease, HAART-associated adverse
effects, nonadherence, and complex drug–drug interactions may
compromise patients’ quality of life.2,3
The nonnucleoside reverse transcriptase inhibitor efavirenz-based
treatment regimens represent the cornerstone of HIV therapy and are
widely used worldwide as the initial preferred therapy in treatment-
naïve HIV patients.4 Efavirenz is generally well tolerated, but common
adverse effects such as central nervous system symptoms (in 50% of
patients),5 metabolic disorders,6 and hepatic injury7 compromise the
safe use of efavirenz. Some of these adverse effects (eg, neuropsychi-
atric effects) are the main reason for early discontinuation of
efavirenz-based therapy in patients.8,9 In addition, certain studies
and case reports have identiﬁed other adverse effects such as
gynacomastia, hematologic abnormalities, abnormal vision, osteoma-
lacia, and hypersensitivity reactions6,10 in patients treated with
efavirenz-based therapy. These adverse effects are important because
they may affect drug adherence that promotes viral resistance and
may cause withdrawal of an otherwise effective drug regimen.
There is evidence that efavirenz may alter serum concentrations of
endogenous compounds through its interaction with endobiotic-
metabolizing enzymes and transporters. We recently reported11 that
in vivo efavirenz reduces the concentrations of bilirubin, a substrate of
uridine glucuronosyltransferase (UGT) 1A1, organic anion transporting
polypeptide (OATP) 1B1, and multidrug resistance-associated protein
(MRP) 2. The use of efavirenz-based HIV therapy is associated with
vitamin D deﬁciency and increased alkaline phosphatase,12,13 probably
through effects of efavirenz on vitamin D-metabolizing enzymes.14,15
In patients with HIV-1 infection, particularly those with AIDS, hem-
atologic adverse effects such as anemia occur at high frequency and
are associated with poor prognosis.16 It is believed that the infection
itself is a risk factor, but certain combination antiretrovirals (eg,
azidothymidine-containing) also lead to hematologic adverse effects.17
In certain case reports, efavirenz-based therapy has been implicated in
immune-mediated hemolytic anemia,18 increased hemoglobin over
time,19 and neutropenia.20 Despite the evidence that efavirenz is
implicated in altered endogenous laboratory markers of safety, making
a direct link between efavirenz and safety laboratory values is difﬁcult
because efavirenz is used in combinationwith other drugs (often used
with 2 nucleoside reverse transcriptase inhibitors or a nucleoside
reverse transcriptase inhibitor and nucleotide reverse transcriptase
inhibitor and it remains unknown whether the changes reported are
speciﬁc to efavirenz or the other components of HAART. The presence
of HIV infection also confounds interpretation of these data.Baseline lab
600 mg/d 
600 mg Efavirenz (EFV)
CYP probe substrates
Single dose PK
Sampling (7 days)
Multiple EFV 
Screening Efavirenz (EFV) PK
CYP Cocktails PK
Figure 1. Study design schema. CYP ¼ cytochrome p450; EFThe effect of efavirenz monotherapy on hematologic and
biochemical safety laboratory values was assessed in a clinical
trial in healthy male and female volunteers primarily designed to
determine the pharmacokinetics and drug interactions of a single
dose and multiple doses of efavirenz.21,22 Serum chemistries
measured at study entry (ie, screening and before efavirenz
administration) and 1 week after completion of the entire study
(exit and 1 week after the ﬁnal dose of efavirenz) were compared.Materials and Methods
Study subjects
Healthy nonsmoking male and female volunteers (aged 18–49
years) who fulﬁlled eligibility criteria (no concurrent medication
use) were enrolled in a trial at the Indiana University School of
Medicine Clinical Research Center. Volunteers were judged to be
healthy by medical history, physical examination, and standard
screening laboratory tests. Detailed inclusion and exclusion criteria
have previously been described.21,22 The Indiana University School
of Medicine Institutional Review Board approved this study and all
volunteers signed an institutional review board-approved informed
consent and HIPAA documents before enrollment.
Study design
The protocol was primarily designed to test efavirenz (single
600-mg oral dose) and multiple dose (after 600 mg/d for 17 days
orally) pharmacokinetics and interactions with the activities of
selected cytochrome p450s (CYPs) (ie, CYP1A2, CYP2B6, CYP2C9,
CYP2C19, and CYP3A4), as measured by simultaneous administra-
tion of a single dose of each isoform-speciﬁc probe substrate.
Participants were studied in 3 phases with a total of 2 inpatient
days and a total of 11 outpatient visits. Phase 1 (Day 1): A single
600-mg oral dose of efavirenz and a cocktail of isoform-selective
CYP probe substrates were given to the volunteers and pharma-
cokinetic sampling was performed for 7 subsequent days. Phase 2
(Day 7): Participants began taking efavirenz 600 mg orally each
day for 17 days and pharmacokinetic samples were collected every
third day for measurement of trough concentrations of efavirenz.
Phase 3 (Day 24): Participants took their ﬁnal dose of efavirenz
with the cocktail probes followed by 7 days of pharmacokinetic
sampling. On Day 30 participants completed and exited the trial.
Standard laboratory results were obtained during the screening
phase (ie, baseline and before drug administration) and at exit on
Day 30 (ie, approximately 1 week after the last dose of efavirenz).
The overall study design is presented in Figure 1. Here, we present
a comprehensive analysis of data that relate to the inﬂuence of
efavirenz monotherapy on exit laboratory values compared with
those obtained at baseline.Exit lab
EFV (17 days)
600 mg Efavirenz (EFV)
CYP probe substrates
trough
EFV PK
CYP Cocktails PK
Steady-state PK
Sampling (7 days)
V ¼ efavirenz; PK ¼ pharmacokinetic; mg/d = mg/day.
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Laboratory data at baseline were compared with data at exit
using 2-tailed, paired Student t test. A P value o 0.05 was
considered to be statistically signiﬁcant. Pearson correlation coef-
ﬁcient was obtained. All statistical analyses were performed using
GraphPad Prism version 5.00 for Windows (GraphPad Software,
San Diego, California).Results
The study included 73 volunteers (71.2% white, 21.9% African
American, and 6.8% other races); 60 subjects who fully completed
the study (30 days) and 13 subjects who partially completed the
study. In Table I, means (SD) and percent change in laboratory
values are presented for the 60 subjects who fully completed the
study (38 men and 22 women).
Marked reduction in total bilirubin was observed at exit
compared with screening (see Table I and Figure 2A). The mean
percent change in total bilirubin was 30%, with extensive
intersubject variability (Figure 2B). We found no correlation
between bilirubin baseline concentrations and percent change in
total bilirubin concentrations at exit (after multiple doses of
efavirenz) relative to screening (before efavirenz administration)
in healthy volunteers (Pearson r ¼ 0.04; P ¼ 0.76; n ¼ 60). The
percent changes were in part explained by intersubject differences
in baseline total bilirubin because there was a signiﬁcant correla-
tion between baseline (screening) values and percent change atTable I
Demographic and clinical laboratory values before and 1 week after pretreatment with
Measure Screening
Sex (M/F) 38/22
Race (white/black/other) 44/12/4
’——————————————
Age (y) 28.1 (9.8)
Weight (kg) 74.4 (14.0)
Body mass index 24.2 (3.9)
Sodium (mmol/L) 139.7 (2.1)
Potassium (mmol/L) 3.88 (0.23)
Chloride (mmol/L) 103.9 (2.6)
Carbon dioxide (mmol/L) 28.65 (1.78)
Blood urea nitrogen (mg/dL) 10.92 (4.0)
Anion (mmol/L) 7.22 (1.95)
Creatinine (mg/dL) 0.92 (0.20)
Calcium (mg/dL) 9.45 (0.31)
Albumin (g/dL) 4.12 (0.29)
Protein (g/dL) 7.11 (0.47)
Total bilirubin (mg/dL) 0.89 (0.42)
Alkaline phosphatase (units/L) 59.9 (14.9)
Aspartate aminotransferase (units/L) 22.59 (4.53)
Alanine aminotransferase (units/L) 19.15 (7.28)
Hemoglobin (g/dL) 14.38 (1.09)
Red blood cell (million/cu mm) 4.73 (0.36)
Hematocrit (%) 41.93 (3.0)
White blood cell (k/cu mm) 6.21 (1.33)
Absolute neutrophil count (k/cu mm) 3.68 (1.14)
Mean corpuscular volume (fL) 89.0 (3.4)
Mean corpuscular hemoglobin (pg) 30.5 (1.2)
Mean corpuscular hemoglobin concentration (GM/dL) 34.3 (0.7)
Red blood cell distribution width (%) 13.0 (0.8)
Meran platelet volume (fL) 8.4 (0.8)
Platelet count (k/cumm) 254.9 (61.3)
Lymphocytes (k/cumm) 1.83 (0.4)
Monocytes (k/cumm) 0.49 (0.15)
Eosinophils (k/cumm) 0.21 (0.51)
Basophils (k/cumm) 0.010 (0.030)
nPercent change at exit relative to screening.
†P value comparing screening and exit (2-tailed, paired Student t test). P o 0.05 wexit (Pearson r ¼ –0.43; P ¼ 0.0006). At screening, 16.6% of
subjects had bilirubin values 4 1 mg/L, whereas only 5% (n ¼ 3)
had values 4 1 mg/dL at exit. Of note, 2 subjects with known
Gilbert syndrome showed a marked decreased in total bilirubin at
exit (–50% and –66.7%) compared with screening. This reduction
was much greater than the average percent change from the rest of
subjects, which was 29%. Because bilirubin is a breakdown
product of hemoglobin, correlations between bilirubin and hemo-
globin levels were performed. As shown in Figure 3, no signiﬁcant
correlation was found between percent changes in hemoglobin
versus percent change in bilirubin, suggesting that the effect of
efavirenz on bilirubin concentration is independent of its possible
effect on hemoglobin. Similarly, percent change in bilirubin did not
correlate with percent change in red blood cell counts (Pearson
r ¼ 0.18 and P ¼ 0.17) (data not shown).
As shown in Figure 4, total bilirubin serum concentrations in
subjects who partially completed the study phases (ie, those who
received 0 or up to 8 doses of efavirenz) compared with those who
fully complete the study are displayed. As the number of efavirenz
doses (days of treatment with efavirenz) increased, the extent of
reduction in total bilirubin concentration tended to increase.
As shown in Table I, hemoglobin was signiﬁcantly lower at exit
(approximately 1 week after the last dose of efavirenz) compared
with those values at screening (before initiation of efavirenz
dosing). Hemoglobin was reported as a percentage due to the
differences in standard normal values for men and women. The
average (SD) percent change in hemoglobin was –8.6% (5.4%), with
substantial between subject variability (5.4% to –20.6%). Baseline
hemoglobin did not predict percent change (Pearson r ¼ –0.05;efavirenz (600 mg/d for 17 days) in healthy volunteers (n ¼ 60).
Exit % Change* P value†
————————Mean (SD)——————————————————-
- -
- -
- -
139.2 (1.7) –0.38 (1.69) 0.079
3.74 (0.26) –3.13 (7.9) 0.0017
105.3 (2.4) 1.40 (3.22) 0.0017
27.27 (1.89) –4.65 (6.55) o0.0001
10.78 (3.29) 7.40 (38.42) 0.77
6.66 (1.52) –0.91 (38.42) 0.075
0.87 (0.16) –3.41 (15.78) 0.01
9.11 (0.33) –3.5 (3.95) o0.0001
3.86 (0.31) –6.44 (7.62) o0.0001
6.61 (0.45) –6.93 (7.47) o0.0001
0.58 (0.22) –29.93 (27.20) o0.0001
62.8 (18.2) 5.15 (13.73) 0.0125
22.92 (8.17) 3.31 (26.67) 0.69
20.88 (11.75) 8.56 (32.78) 0.13
13.14 (1.22) –8.6 (5.4) o0.0001
4.30 (0.40) –8.9 (5.2) o0.0001
38.23 (3.38) –8.8 (5.6) o0.0001
5.60 (1.51) –9.1 (17.6) o0.0001
3.11 (1.13) –13.9 (22.8) o0.0001
89.0 (3.4) 0.03 (1.8) 0.94
30.6 (1.3) 0.3 (2.1) 0.26
34.4 (0.7) 0.2 (1.8) 0.43
13.1 (0.7) 0.3 (4.0) 0.79
8.4 (0.8) 0.4 (4.1) 0.63
243.6 (60.5) –3.6 (13.2) 0.02
1.82 (0.53) 1.9 (31.8) 0.92
0.46 (0.17) –4.1 (29.2) 0.08
0.17 (0.12) 19.5 (74.2) 0.59
0.013 (0.034) –33.3 (51.6) 0.42
as considered to be statistically signiﬁcant.
3P = 3.7*10–10
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Figure 2. Effect of multiple doses (600 mg/d for 17 days) efavirenz on total bilirubin in healthy volunteers (n ¼ 60). (A) Total bilirubin at screening (before efavirenz
treatment) versus exit (1 week after the ﬁnal efavirenz dose). (B) Percent change at exit relative to screening in individual subjects (average percent change [SD]).
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bin count within normal range at screening was an inclusion
criterion to participate in the study. Of 60 subjects who completed
the entire study, 34 (56.7%) developed clinical anemia at exit,
which was normocytic in each case, although subjects were
asymptomatic on exit evaluation. Normal ranges for hemoglobin
and hematocrit for men are 13.5 to 17.5 g/dL and 41% to 53%,
respectively, whereas normal ranges for hemoglobin and hema-
tocrit for women are 12 to 16 g/dL and 36% to 46%, respectively.
Reductions in hemoglobin and hematocrit were highly signiﬁcant
(P o 0.0001) (Table I). As expected, red blood cell counts were
signiﬁcantly decreased at exit compared with screening; red blood
cell indices, including mean corpuscular volume, mean corpuscu-
lar hemoglobin, mean corpuscular hemoglobin concentration, and
red blood cell distribution width remained normal between
screening and exit in all subjects (Table I).
Upon the recommendation of the data and safety monitoring
board, any subject with hemoglobin levels o 12 g/dL at study exit
was required to return to our clinical research center for a follow-up
safety assessment. A total of 23 subjects had hemoglobin levels o 12
g/dL at study exit. None of these subjects were treated with iron. Of
these, 15 subjects with evidence of anemia at exit failed to return for
follow-up complete blood cell count. One subject was excluded100
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Figure 3. Pearson correlation between percent changes in hemoglobin concentra-
tions and percent change in total bilirubin concentrations at exit (after multiple
doses of efavirenz) relative to screening (before efavirenz administration) in
healthy volunteers (n ¼ 60).because of incomplete data at exit. Only 7 subjects returned for
follow-up and had complete blood cell analyses. Supplemental
Figure 1 shows slow recovery of hemoglobin during the follow-up
period (1 month after exit) after discontinuation of efavirenz for the
subjects (n ¼ 7) who returned for repeat evaluation.
As shown in Table I, absolute neutrophil count (ANC) was
signiﬁcantly lower at exit than at screening (–13.9% [22.8%]).
Whereas the majority of subjects (80%) showed decreased neu-
trophil count at exit (–3.2% to –54.6%), an increase was observed in
20% of subjects (2%–83%). Baseline ANC did not correlate with
changes at exit (Pearson r ¼ –0.20; P ¼ 0.12). Reductions in total
white blood cell and ANC between screening and exit were highly
statistically signiﬁcant (P o 0.0001). However these decreases in
total white blood cell count and ANC were generally within the
normal range in these healthy volunteers.1.0
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Figure 4. Total bilirubin concentrations in patients who partially completed the
different phases of the study compared with those who fully completed the study
and to the screening values. Subjects in the 1-dose group only completed Phase 1
(only 1 dose of efavirenz) and did not receive additional doses of efavirenz. Patients
in the 2 to 9 doses groups discontinued at different stages during Phase 2 of the
study; that is, after taking 1 (600 mg), 3 (600 mg/d for 3 days), and 8 (600 mg/d for
8 days) doses of efavirenz during Phase 2 at home.
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creatinine, and liver enzymes are listed in Table I. Marginal but
statistically signiﬁcant reduction in certain values was observed,
whereas others showed no difference.
We explored whether efavirenz exposure predicts changes in
the laboratory values tested above. Steady-state efavirenz AUC0–24
and the maximum efavirenz plasma concentrations did not corre-
late with any of the laboratory values measured. Also the percent
change of efavirenz exposure (steady-state vs a single dose) did
not correlate signiﬁcantly with percent change of the laboratory
values (exit vs screening) (Supplemental Figure 2).Discussion
In our study, efavirenz monotherapy (600 mg/d) signiﬁcantly
lowered total plasma bilirubin levels at exit compared with
screening values in healthy volunteers, independent of its effect
on hemoglobin. Because exit labs were performed 1 week after the
ﬁnal dose of efavirenz, our data suggest a long offset effect likely
due to the long half-life of efavirenz or the slow turnover of the
endogenous compounds. These data are consistent with a recent
study in a small number of healthy volunteers reporting that both
total and conjugated bilirubin levels were reduced by efavirenz.23
To gain insight into the mechanisms by which efavirenz decreases
bilirubin levels, it is important to brieﬂy point out the complex
hepatobiliary disposition of bilirubin. The disposition of bilirubin
and its conjugated metabolites is complex, involving metabolizing
enzymes and transporters.24,25 Unconjugated bilirubin enters the
hepatocytes via diffusion and/or transport where it undergoes glucur-
onidation by UGT1A1 to mono- and diglucuronides. Before eventually
being secreted into the bile via primarily MRP2, a substantial fraction
of these glucuronides are secreted into blood from the intracellular
compartment and then undergoes reuptake in the cell from the blood
by OATP1B1 and OATP1B3. This secretion and reuptake loop (ie,
sinusoidal liver-to-blood shuttling loop or hepatocyte hopping) may
prevent saturation of biliary excretion in the upstream hepatocytes,
thereby ensuring efﬁcient biliary elimination by MRP2.
It has been well documented that drugs known to activate
constitutive androstane receptor (CAR) (eg, phenytoin and pheno-
barbital) and/or Pregnane X receptor (PXR) (eg, rifampicin and
carbamazepine) upregulate the expression of proteins involved in
bilirubin disposition, including UGT1A1 and MRP2,26,27 and thus
reduce serum bilirubin concentrations.28,29 In fact, phenobarbital
and rifampicin have been used in the past to treat hyperbilirubine-
mia.29,30 Similarly, efavirenz is known to activate CAR11,31 and
possibly PXR,32 and it is reasonable to suggest that efavirenz, like
these PXR/CAR activators, interacts at Z1 of these sites to enhance
the elimination of bilirubin. Considering that bilirubin is mainly
excreted in the bile after conjugation by UGT1A1,33 one potential
pathway by which efavirenz reduces bilirubin serum concentrations
may be its ability to enhance UGT1A1-mediated glucuronidation of
bilirubin into mono- and diglucuronides in the liver. Indeed,
efavirenz-based therapy has been reported to reverse hyperbiliru-
binemia induction by indinavir and atazanavir, drugs that are
known to inhibit UGT1A1 activity.34 The possibility that reduced
effective inhibitory concentrations (exposure) of these UGT1A1
inhibitor drugs by efavirenz may contribute to this observation
cannot be ruled out given that efavirenz enhances the elimination
of indinavir35 and atazanavir.36 However the ability of efavirenz to
lower serum concentrations of bilirubin was demonstrated in the
absence of these UGT1A1 inhibitors.11,23 Of note, efavirenz has been
reported to enhance the elimination of drugs that are substrates of
UGT1A1, including dolutegravir.37 The second possible mechanism
by which rifampin decreases bilirubin concentrations may involve
induction of MRP2, which has been shown to facilitate efﬂuxtransport of bilirubin glucuronides in to the bile.38 Although only
total bilirubin was measured in our study, there is evidence that
efavirenz reduces the concentrations of bilirubin glucuronides,23
supporting efavirenz-mediated efﬂux transport of the conjugate
into the bile. Our data suggest that efavirenz enhances bilirubin
elimination through induction of UGT1A1 and MRP2, although the
contribution of other mechanisms (eg, inhibition of MRP3 or
induction of uptake such as OATPs) cannot be fully excluded.
Together our ﬁndings help explain reversal by efavirenz of hyper-
bilirubinemia induction by some protease inhibitor antiretroviral
drugs (eg, indinavir and atazanavir). Efavirenz is expected to alter
the pharmacokinetics of coadministered drugs through similar
mechanisms (modulating UGT1A1 or drug transporters). Through
activation of CAR and PXR,11,31 two key regulators of drug and
endobiotic disposition and genes, efavirenz, besides bilirubin, likely
modulate the disposition of many endogenous compounds. For
example, the use of efavirenz-based HIV therapy is associated with
vitamin D deﬁciency and increased alkaline phosphatase,12,13 and
this effect is believed to be due to effect of efavirenz on 24-
hydroxylase,15 an enzyme responsible for the inactivation of 25-
hydroxy vitamin D and 1,25-dihydroxy vitamin D.14 Complex drug
interactions with efavirenz have been well documented.6 Our data
suggest that efavirenz may inﬂuence homeostasis through effects
on the disposition of endogenous compounds.
According to the efavirenz package insert, different efavirenz-
based therapies were reported to be associated with neutrophils
o 750/mm3 in 2% to 10% of subjects. In 1 case report, initiation of
efavirenz-based therapy was reported to exacerbate HIV-related
neutropenia, an effect that persisted for the entire time efavirenz
was taken and resolved when efavirenz was discontinued.20 In our
study, efavirenz monotherapy signiﬁcantly decreased ANC, consistent
with the above-mentioned data. We also found substantial decrease
in hemoglobin at exit compared with screening, with about 56% of
subjects developing nonsymptomatic anemia. However, our data
were obtained and analyzed without a control group of volunteers
who took placebo instead of efavirenz. Although this anemia was
observed 1 week after the intensive blood sampling during the ﬁnal
phase (Phase 3) inpatient visit, we cannot rule out the possibility that
the low values of hemoglobin (and possibly cell counts) at exit may
simply reﬂect blood drawn during the intensive pharmacokinetic
sampling (500 mL blood across 30 days).39,40 Therefore our ﬁndings
should be viewed as hypothesis generation that requires further
validation in placebo-controlled settings, and, if found positive, the
mechanisms involved need to be identiﬁed and the clinical signiﬁ-
cance in the target population (patients with HIV-1) established.Conclusions
Multiple doses of efavirenz monotherapy reduce total bilirubin
levels. These data suggest that efavirenz may inﬂuence disposition
of coadministered drugs or endogenous compounds relevant in
homeostasis through upregulation of genes involved in bilirubin
metabolism and transport. Although anemia and decreased ANC
were common during efavirenz monotherapy in our study, further
study is needed to conﬁrm whether these effects are due to blood
loss resulting from intensive pharmacokinetic sampling or a direct
adverse effect of efavirenz.Acknowledgments
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